WESTBROOK, Maine, July 30,
2024 /PRNewswire/ -- IDEXX Laboratories,
Inc. (NASDAQ: IDXX), a global leader in pet healthcare
innovation, today published its 2023 Corporate Responsibility
Report "Enhancing the Health and Well-being of Pets, People, and
Livestock for 40 Years" highlighting progress against its corporate
responsibility goals.
The Care We Advance
IDEXX brings clarity to the complex world of veterinary medicine
through diagnostic insights and software solutions that support
longer, fuller lives for pets and those who care for them. Key
highlights from the report include:
- Expanded IDEXX Reference Laboratories menu with the launch of
IDEXX Cystatin B Test in North
America, adding kidney injury detection to the most
comprehensive menu for kidney health in the industry.
- Advanced the development of several new innovative product
launches planned for 2024, including the IDEXX inVue
Dx™ Cellular Analyzer and Fecal Dx™ antigen testing expansion
with Cystoisospora detection.
- Supported underserved communities by enabling access to care
for over 245,000 animals in 2023, with a cumulative total of over
625,000 animals through our global social initiatives since
2022.
The People We Support
IDEXX strives to foster a collaborative and inclusive workplace
that empowers our employees to develop and grow and find purpose
and fulfillment in all they do. Key highlights from the report
include:
- Maintained gender balance in global management roles and
continued to support women in STEM.
- Supported achieving over 18,000 logged employee volunteer
hours, exceeding the Company's 2025 goal of 15,000 annual volunteer
hours.
- Logged over 73,000 hours of learning and development.
The Planet We Share
IDEXX recognizes the importance of protecting the planet and its
relationship to animal and human health. Key highlights from the
report describe IDEXX's progress towards achieving its greenhouse
gas emissions reduction goals and include:
- Procured a virtual power purchase agreement with a solar
developer to support the development of new, clean electricity in
North America.
- Installed a dual-source energy system at our core European
reference laboratory in Kornwestheim, Germany, enabling this location to purchase
power under a renewable electricity supply contract.
- Updated SNAP™ Feline Triple™ Test so that it can be shipped at
room temperature, reducing shipping emissions, packaging, and
waste.
"Our progress against our corporate responsibility goals and
commitments in 2023 continues to be closely aligned with our
business strategy and innovation agenda," said Jay Mazelsky, IDEXX President and Chief
Executive Officer. "This would not be possible without the
coordinated and focused efforts of our global employees. I am
extremely grateful and appreciative of their outstanding work and
commitment."
IDEXX's 2023 report focuses on IDEXX's key corporate
responsibility topics in alignment with reporting standards and
frameworks, such as those released by the Sustainability Accounting
Standards Board and the Task Force on Climate-Related Financial
Disclosures, as well as our business strategy. Read the 2023
Corporate Responsibility Report here.
About IDEXX
IDEXX is a global leader in pet healthcare
innovation. Our diagnostic and software products and services
create clarity in the complex, constantly evolving world of
veterinary medicine. We support longer, fuller lives for pets by
delivering insights and solutions that help the veterinary
community around the world make confident decisions—to advance
medical care, improve efficiency, and build thriving practices. Our
innovations also help ensure the safety of milk and water across
the world and maintain the health and well-being of people and
livestock. IDEXX Laboratories, Inc. is a member of the S&P
500® Index. Headquartered in Maine, IDEXX employs approximately 11,000
people and offers solutions and products to customers in more than
175 countries and territories. For more information about IDEXX,
visit idexx.com.
Note Regarding Forward-Looking Statements
This news
release contains or may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by the use of
words such as "expects," "may," "anticipates," "intends," "would,"
"will," "plans," "believes," "estimates," "should," "project," and
similar words and expressions. These forward-looking statements are
intended to provide our current expectations or forecasts of future
events; are based on current estimates, projections, beliefs, and
assumptions; and are not guarantees of future performance. Actual
events or results may differ materially from those described in the
forward-looking statements. These statements are subject to risks,
uncertainties, assumptions, and other important factors. Readers
are cautioned not to put undue reliance on such forward-looking
statements because actual results may vary materially from those
expressed or implied. The reports filed by IDEXX pursuant to
United States securities laws
contain discussions of some of these risks and uncertainties. IDEXX
assumes no obligation to, and expressly disclaims any obligation
to, update or revise any forward-looking statements, whether as a
result of new information, future events, or otherwise. Readers are
advised to review IDEXX's filings with the United States Securities
and Exchange Commission (which are available from the SEC's EDGAR
database at sec.gov and via IDEXX's website at idexx.com).
View original content to download
multimedia:https://www.prnewswire.com/news-releases/idexx-releases-2023-corporate-responsibility-report-highlighting-progress-against-its-goals-302208981.html
SOURCE IDEXX Laboratories, Inc.
